InNexus Biotechnology Current Valuation vs. Total Asset
InNexus Biotechnology Total Asset vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining InNexus Biotechnology's current stock value. Our valuation model uses many indicators to compare InNexus Biotechnology value to that of its competitors to determine the firm's financial worth. InNexus Biotechnology is considered the number one company in current valuation category among its peers. It is rated below average in total asset category among its peers fabricating about 0.51 of Total Asset per Current Valuation. The ratio of Current Valuation to Total Asset for InNexus Biotechnology is roughly 1.95 . Comparative valuation analysis is a catch-all technique that is used if you cannot value InNexus Biotechnology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.InNexus Current Valuation vs. Competition
InNexus Biotechnology is considered the number one company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 20.91 Million. InNexus Biotechnology totals roughly 6.69 Million in current valuation claiming about 32% of equities under Health Care industry.
InNexus Total Asset vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
InNexus Biotechnology |
| = | 6.69 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
InNexus Biotechnology |
| = | 3.44 M |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
InNexus Total Asset Comparison
InNexus Biotechnology is currently under evaluation in total asset category among its peers.
InNexus Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in InNexus Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, InNexus Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of InNexus Biotechnology's change in net profit over the period of time. It can combine multiple indicators of InNexus Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
InNexus Biotechnology, Inc., a development stage company, engages in the commercialization of monoclonal antibodies based on its Dynamic Cross Linking technology. InNexus Biotechnology, Inc. is headquartered in Vancouver, Canada. Innexus Biotechnology is traded on OTC Exchange in the United States.
InNexus Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on InNexus Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of InNexus Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the InNexus Biotechnology's important profitability drivers and their relationship over time.
InNexus Biotechnology Earnings per Share Projection vs Actual
Use InNexus Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if InNexus Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in InNexus Biotechnology will appreciate offsetting losses from the drop in the long position's value.InNexus Biotechnology Pair Trading
InNexus Biotechnology Pair Trading Analysis
The ability to find closely correlated positions to InNexus Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace InNexus Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back InNexus Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling InNexus Biotechnology to buy it.
The correlation of InNexus Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as InNexus Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if InNexus Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for InNexus Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your InNexus Biotechnology position
In addition to having InNexus Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large & Mid Caps ETFs Thematic Idea Now
Large & Mid Caps ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large & Mid Caps ETFs theme has 87 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large & Mid Caps ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in InNexus Stock
If you are still planning to invest in InNexus Biotechnology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InNexus Biotechnology's history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |